clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT04746963 |
P6099 | clinical trial phase | phase I clinical trial | Q5452194 |
phase II clinical trial | Q42824440 | ||
P17 | country | United States of America | Q30 |
P582 | end time | 2022-08-01 | |
P921 | main subject | eye disease | Q3041498 |
P1050 | medical condition | macular degeneration | Q27429789 |
P2899 | minimum age | 50 | |
P1132 | number of participants | 18 | |
P8005 | research subject recruitment status | recruiting | Q76649708 |
P1813 | short name | SHASTA | |
P580 | start time | 2021-02-01 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | Phase 1/2a Study of the Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD) |
Search more.